Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
148.53B
Market cap148.53B
Price-Earnings ratio
23.75
Price-Earnings ratio23.75
Dividend yield
2.61%
Dividend yield2.61%
Average volume
7.19M
Average volume7.19M
High today
$121.38
High today$121.38
Low today
$114.02
Low today$114.02
Open price
$115.22
Open price$115.22
Volume
13.12M
Volume13.12M
52 Week high
$121.38
52 Week high$121.38
52 Week low
$72.43
52 Week low$72.43

GILD News

Benzinga 2d
Why Is Gilead Sciences Stock Surging Friday? - Gilead Sciences - Benzinga

...

Why Is Gilead Sciences Stock Surging Friday? - Gilead Sciences - Benzinga
Seeking Alpha 2d
Gilead Sciences in charts: HIV, oncology sales climb as revenue from other products falls YY

Earnings News Healthcare Gilead Sciences in charts: HIV, oncology sales climb as revenue from other products falls YY Aug. 07, 2025 5:57 PM ET Gilead Sciences,...

Gilead Sciences in charts: HIV, oncology sales climb as revenue from other products falls YY
Seeking Alpha 2d
Gilead Sciences raises 2025 outlook, beats Q2 expectations

Gilead Sciences (NASDAQ:GILD) shares ticked up after the company raised full year sales and profit outlook, helped by growing demand for its HIV products. The...

Gilead Sciences raises 2025 outlook, beats Q2 expectations

Analyst ratings

77%

of 26 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
VeriSign
Exelixis
United Therapeutics
Vertex Pharmaceuticals
Sprouts Farmers Market
Spotify
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.